Request for Letters of Interest (LOI) for NCI-ComboMATCH Laboratories; Extension of Submission Period

---
identifier: "/us/fr/2023-21758"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Request for Letters of Interest (LOI) for NCI-ComboMATCH Laboratories; Extension of Submission Period"
title_number: 0
title_name: "Federal Register"
section_number: "2023-21758"
section_name: "Request for Letters of Interest (LOI) for NCI-ComboMATCH Laboratories; Extension of Submission Period"
positive_law: false
currency: "2023-10-03"
last_updated: "2023-10-03"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2023-21758"
document_type: "notice"
publication_date: "2023-10-03"
agencies:
  - "Health and Human Services Department"
  - "National Institutes of Health"
fr_citation: "88 FR 68123"
fr_volume: 88
comments_close_date: "2023-08-14"
fr_action: "Notice; extension of submission period."
---


#  Request for Letters of Interest (LOI) for NCI-ComboMATCH Laboratories; Extension of Submission Period

**AGENCY:**

National Institutes of Health, HHS.

**ACTION:**

Notice; extension of submission period.

**SUMMARY:**

The Department of Health and Human Services, National Institutes of Health (NIH) published a Notice in the *Federal Register* on August 14, 2023. This document extends the date to submit Letters of Interest (LOIs) to the National Cancer Institute (NCI), NIH.

**DATES:**

The deadline to submit LOIs for NCI-ComboMATCH Laboratories, which published at 88 FR 55055 on August 14, 2023, is extended. LOIs should be submitted before 5 p.m. EST on October 31, 2023.

**FOR FURTHER INFORMATION CONTACT:**

Questions about this request for LOIs should be directed to *[email protected]* or Benjamin Kim at *[email protected]* or by phone at (240) 276-5961.

**SUPPLEMENTARY INFORMATION:**

On August 14, 2023, NIH published a notice in the *Federal Register* , FR Doc. 2023-17352, on pages 55055-55057. This notice extends the submission date for LOIs from September 30, 2023, to October 31, 2023.

Lyndsay N. Harris,

Associate Director, Cancer Diagnosis Program, Division of Cancer Treatment & Diagnosis, National Cancer Institute.